XELOX方案化疗在老年结肠癌患者根治术后应用的效果

Efficacy of Senior Colonic Cancer Patients Postoperatively Received Chemotherapy of XELOX Scheme

为探讨XELOX方案化疗在老年结肠癌患者根治术后应用的效果,将2016年1月至2018年4月于我院接受结肠癌根治术治疗的120例老年患者随机分为观察组和对照组,各60例,术后第5周开始,观察组接受XELOX方案化疗,对照组接受FOLFOX方案化疗。比较2组患者化疗前后患者免疫功能,以及术后2年无病生存率(DFS)、总生存率(OS)。结果显示,化疗前2组患者CD_(3)^(+)、CD_(4)^(+)、CD_(8)^(+)、NK细胞水平比较差异均无统计学意义,P>0.05;化疗后,观察组患者CD_(3)^(+)、CD_(4)^(+)、CD_(8)^(+)、NK细胞水平明显高于对照组,P<0.05。观察组患者术后2年DFS、OS均略高于对照组,但差异无统计学意义,P>0.05。结果表明,与FOLFOX方案化疗相比,老年结肠癌患者根治术后接受XELOX方案化疗可在一定程度上延长患者生存时间,改善患者免疫功能。

This study was to investigate the efficacy of senior colonic cancer patients received chemotherapy of XELOX scheme after surgery,randomly divided 120 senior colonic cancer patients treated in authors’ hospital(2016-01-2018-04)into observation group(60 cases)and control group(60 cases),from 5 th week after surgery the former started to receive XELOX scheme chemotherapy,while the latter received FOLFOX scheme chemotherapy;then,compared both groups’ patients’ immuno-function before and after chemotherapy,as well as disease-free survival rate(DFS)within 2 years after surgery,and overall survival rate(OS).As results,before chemotherapy both groups’ patients’ levels of CD_(3)^(+),CD_(4)^(+),CD_(8)^(+),and NK cells had no statistical difference(P >0.05);after chemotherapy,above-mentioned levels of observation group were significantly higher than that of control group(P<0.05);at 2 years after surgery OS and DFS of observation group were slightly higher than that of control group,but there was no statistical difference(P >0.05).Results show that compared with FOLFOX scheme chemotherapy,XELOX scheme chemotherapy can lengthen survival time,and improve patients’ immuno-function at certain content.